- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04610138
Study of ZnAg Liquid Solution to Treat COVID-19 Symptomatic Participants
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of ZnAg Liquid Solution to Treat COVID-19 in Acutely Symptomatic Non-Hospitalized Participants
Study Overview
Detailed Description
This is a multi-site, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of ZnAg liquid solution in symptomatic participants with acute COVID-19 (PCR documented SARS-CoV-2 infection) that are not hospitalized at the time of enrollment (e.g., present to an emergency room without being admitted to the hospital or diagnosed in an outpatient clinic setting).
Participants must have presented with two or more symptoms of acute COVID-19 (within 96 hours prior to the Baseline visit) self-reported as moderate or severe at the Baseline visit, including fever, myalgia, fatigue, chest tightness, chills, cough, diarrhea, gastrointestinal distress, headache, sore throat, congestion or runny nose, ageusia, anosmia, nausea, tingling or numbness in the extremities, or shortness of breath. SARS-CoV-2 infection must be confirmed by polymerase chain reaction (PCR) testing within 96 hours prior to the Baseline visit.
Participants who meet all inclusion criteria and none of the exclusion criteria and who formally consent to participate will be randomized 1:1:2 to receive ZnAg (low dose) : ZnAg (high dose) placebo in a double-blind fashion in addition to standard supportive care. Within the active treatment arm, participants will be randomized to receive either low or high dose ZnAg.
- Active treatment with 60 ml low-dose ZnAg (Zn 6 ug/ml and Ag 10 ug/ml; equivalent to 0.6 mg Ag, 0.36 mg Zn), po q12 hours or;
- Active treatment with 60 ml high-dose ZnAg (Zn 12 ug/ml and Ag 20 ug/ml; equivalent to 1.2 mg Ag, 0.72 mg Zn), po q12 hours;
- 60 ml matching placebo, po q12 hours
Participants who become clinically unstable during the course of the study (e.g., requiring high-flow supplemental oxygen or mechanical ventilatory support) per the judgement of the site investigator will be admitted to a hospital and their clinical status (e.g., vital status, hospitalization status, respiratory status, COVID-19 ordinal scale) will continue to be tracked per protocol.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Recife
-
Santo Amaro, Recife, Brazil, 89020-430
- Procape
-
-
Rio De Janeiro
-
Centro, Rio De Janeiro, Brazil, 20020-000
- Projeto Praca Onze
-
Gloria, Rio De Janeiro, Brazil, 20241-180
- IBPClin
-
-
Sau Paulo
-
Campinas, Sau Paulo, Brazil, 14.784-400
- Casa de Saúde
-
-
State Of Sau Paulo
-
Sao Paulo, State Of Sau Paulo, Brazil, 13.060-080
- IPECC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults, aged 40 - 90 years (inclusive)
- Acute onset (within 96 hours of the Baseline visit) of two or more COVID-19 symptoms self-rated as moderate-to-severe, including fever, myalgia, fatigue, chest tightness, chills, cough, diarrhea, gastrointestinal distress, headache, sore throat, congestion, or runny nose, ageusia, anosmia, nausea, tingling or numbness in the extremities, or shortness of breath.
- Laboratory-confirmed SARS-CoV-2 infection as determined by positive PCR in a sample collected ≤ 96 hours prior to the Baseline visit.
- PGI-Severity and CGI-Severity assessments of 'Mild', 'Moderate, or 'Severe' at the Screening visit (e.g., cannot be 'Normal').
- Participant (or legally authorized representatives) provides informed consent prior to the initiation of any study procedures.
- Participant is willing and able to follow all study procedures and assessments according to the study protocol.
- Participant is able to consume 60 ml of fluid orally twice daily.
- Women of childbearing potential must agree to either abstinence or use at least one primary form of contraception, not including hormonal contraception from the time of screening through the end of study.
Exclusion Criteria:
- Unable or unwilling to take ZnAg liquid solution or matching placebo as directed.
- Hospitalized prior to Baseline for COVID-19 management.
- Need for hospitalization and/or ventilatory support at Baseline.
- The emergence of any disease during study, other than COVID-19 that could better explain the participants' signs and symptoms.
- Severe disease: respiratory distress, or requiring supplemental oxygen, or SpO2 ≤ 93% on room air, or tachypnea (respiratory rate ≥ 30 breaths/min) at Baseline.
- History or presence of serious or acute heart disease such as uncontrolled cardiac dysrhythmia or arrhythmia, uncontrolled angina pectoris, cardiomyopathy, or uncontrolled congestive heart failure (NYHA class 3 or 4).
- Legal incapacity or limited legal capacity.
- Women of childbearing potential who do not agree to use either abstinence or at least one primary form of contraception, not including hormonal contraception from the time of screening through the end of the study.
- Pregnant or breastfeeding.
- Participation in another clinical study with an investigational product within the prior 12 months (per Resolution 251/1997).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Active treatment with 60 ml low-dose ZnAg
(Zn 6 ug/ml and Ag 10 ug/ml; equivalent to 0.6 mg Ag, 0.36 mg Zn), po q12 hours
|
ZnAg liquid solution
|
Experimental: Active treatment with 60 ml high-dose ZnAg
(Zn 12 ug/ml and Ag 20 ug/ml; equivalent to 1.2 mg Ag, 0.72 mg Zn), po q12 hours;
|
ZnAg liquid solution
|
Placebo Comparator: 60 ml matching placebo
60 ml matching placebo, po q12 hours
|
Water
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to substantial alleviation of COVID-19 symptoms.
Time Frame: Up to 28 days.
|
Time to substantial alleviation of COVID-19 symptoms up to 28-days, over a continuous period ≥ 48 hours (confirmed symptom resolution), defined as PGI-Severity of 'Normal' in Participants whose Baseline PGI-Severity value was 'Mild'; or, a PGI-Severity of 'Normal' or 'Mild' in participants whose Baseline PGI-Severity value was 'Moderate' or 'Severe'.
|
Up to 28 days.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to complete alleviation of COVID-19 symptoms.
Time Frame: Up to 28 days.
|
Time to complete alleviation of COVID-19 symptoms up to 28- days, over a continuous period ≥ 48 hours (confirmed symptom resolution).
|
Up to 28 days.
|
Proportion of participants who are hospitalized, requires hospitalization or are deceased.
Time Frame: Up to 28 days
|
Proportion of participants who are hospitalized, require hospitalization, or are deceased from Baseline to Day 28.
Hospitalization will be determined by Investigator's clinical judgement.
Where applicable, Investigators should follow local recommendations for hospitalization of patients with COVID-19 within their institution.
|
Up to 28 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of alive hospital free days at Day 28.
Time Frame: 28 days
|
Days from baseline participant remains alive.
|
28 days
|
Mean change from Baseline to Day 8, Day 14, Day 21, and Day 28 in SARS-CoV-2 viral load.
Time Frame: Up to 28 days
|
Mean change from Baseline to Day 8, Day 14, Day 21, and Day 28 in SARS-CoV-2 viral load (Cycle Thresholds, Ct) , and time to non-detectable virus levels assessed by RT-qPCR.
|
Up to 28 days
|
Change from Baseline to Day 8, Day 14, Day 21, and 28 in the slope of oxygen saturation levels (SpO2) assessed per protocol.
Time Frame: up to 28 days
|
Oxygen saturation will be obtained after the participant has been resting for 5 minutes.
|
up to 28 days
|
Clinical Global Impression (CGI) Severity and Change measures from Baseline to Day 8, Day 14, Day 21, and 28.
Time Frame: Up to 28 days
|
Measured by changes in participant rated Clinical Global Impression.
|
Up to 28 days
|
Patient Global Impression (PGI) Severity and Change measures from Baseline to Day 8, Day 14, Day 21, and 28.
Time Frame: Up to 28 days
|
Measured by changes in participant rated Patient Global Impression.
|
Up to 28 days
|
Change in the area under the curve for Net Symptom Burden from Baseline to Day 8, Day 14, Day 21, and 28.
Time Frame: Up to 28 days
|
Summary measure integrating semi-daily serial assessments of a subject's symptom count and severity over the duration of the study.
|
Up to 28 days
|
Change in clinical status from Baseline to Day 8, Day 14, Day 21, and Day 28.
Time Frame: Up to 28 days
|
Assessed by the Clinical Status Ordinal Scale established in the remdesivir ACTT study.
Scale is 1-8, with 1 being the least severe and 8 being the most severe (death).
|
Up to 28 days
|
All-cause mortality rate at Day 28.
Time Frame: 28 days
|
Rate of deceased participants at day 28.
|
28 days
|
Proportion of subjects who have not returned to "normal" at the day 21 and day 28 visits.
Time Frame: 28 days
|
Proportion of subjects who do not have a PGI-Severity or CGI-Severity assessment of "normal" at the day 21 and day 28 visits.
|
28 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CNMZnAg.202
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichEnrolling by invitation
-
Alexandria UniversityCompleted
Clinical Trials on CNM-ZnAg
-
Clene NanomedicineClene Australia Pty LtdTerminatedRelapsing Remitting Multiple Sclerosis | Optic Neuropathy | Optic; Neuritis, With DemyelinationUnited States, Canada, Australia
-
Clene NanomedicineClene Australia Pty LtdCompletedAmyotrophic Lateral SclerosisAustralia
-
Clene NanomedicineUniversity of Texas Southwestern Medical CenterRecruitingMultiple SclerosisUnited States
-
Clene NanomedicineUniversity of Texas Southwestern Medical CenterCompletedParkinson's DiseaseUnited States
-
Clene NanomedicineMassachusetts General HospitalAvailable
-
Clene NanomedicineUniversity of Texas Southwestern Medical CenterWithdrawnAmyotrophic Lateral SclerosisUnited States
-
Clene NanomedicineAvailableAmyotrophic Lateral SclerosisUnited States
-
Merit E. Cudkowicz, MDClene NanomedicineCompleted
-
Drexel UniversityCompleted
-
Clene NanomedicineCompletedHealthy Volunteers - Male and FemaleNetherlands